A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
MDR-TB
Interventions
DRUG

PRS Regimen V

PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)

DRUG

MDR-TB Treatment Regimen(WHO)

Treatment according to WHO MDR-TB treatment guidelines (2019)

Trial Locations (1)

Unknown

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Public Health Clinical Center

OTHER_GOV

collaborator

No.85 Hospital, Changning, Shanghai, China

OTHER

collaborator

Ganzhou Fifth People's Hospital, China

UNKNOWN

collaborator

Weifang Second People's Hospital, China

UNKNOWN

collaborator

Anhui Chest Hospital

OTHER

collaborator

Fourth Taiyuan People's Hospital, China

UNKNOWN

collaborator

Shanghai Pudong New Area Pulmonary Hospital, China

UNKNOWN

collaborator

Huashan Hospital

OTHER

collaborator

Zhengzhou Sixth People's Hospital, China

UNKNOWN

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT05278988 - A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB | Biotech Hunter | Biotech Hunter